December 5th 2023
Frontline treatment with enfortumab vedotin/pembrolizumab is associated with the highest healthcare costs for patients with locally advanced or metastatic urothelial carcinoma.
December 4th 2023
The FDA has granted enfortumab vedotin plus pembrolizumab priority review status for patients with locally advanced or metastatic urothelial cancer following data from the phase 3 EV-302/KEYNOTE-A39 trial.
October 23rd 2023
Nivolumab plus gemcitabine-cisplatin improved overall and progression-free survival in unresectable or metastatic urothelial carcinoma.
For the first time, a new therapeutic regimen outperformed chemotherapy in improving overall survival in frontline urothelial cancer.
July 31st 2023
Patients with nonmetastatic clinically node positive bladder cancer who wish to avoid major surgery may achieve similar clinical outcomes with trimodal therapy.
Frontline Enfortumab Vedotin/Pembrolizumab Shows Continued Efficacy in Advanced Urothelial Carcinoma at 4-Year Follow-Up
Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.
Patients With DRD+ Metastatic Urothelial Cancer Achieve Prolonged PFS with Rucaparib Maintenance Therapy
Rucaparib may be a viable maintenance therapy option for patients with DNA repair–deficient positive, metastatic urothelial cancer who are unlikely to benefit from avelumab immunotherapy.
Immunotherapy Is Promising for Cisplatin-Ineligible Metastatic Urothelial Cancer
Several trials in the field of first-line metastatic urothelial cancer are testing combinations with gemcitabine/platinum-based therapy followed by maintenance avelumab.
GU Nurse Talks Exciting Advancements in Bladder Cancer
Nurses must stay up to date with the fast-moving world of bladder cancer.
Accelerated Chemo Regimen Extends OS in Neoadjuvant Bladder Cancer Treatment
Neoadjuvant chemotherapy with dose-dense MVAC extends overall survival compared with other chemo regimens in bladder cancer treated with cystectomy.
Genetic Test Aims to Prevent Over-Treatment, Lower Care Costs in Bladder Cancer
A new test that identifies which bladder cancer tumors will become invasive could help reduce health care costs and over-treatment in patients.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512